Kenya project aims to eradicate cervical cancer with HPV vaccine and better screening

NCT ID NCT07240220

Not yet recruiting Prevention Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study continues a community project in rural Kenya to prevent cervical cancer. It offers the 9-valent HPV vaccine to 2000 adolescent girls and tests self-collected swabs for high-risk HPV in adult women. Researchers will also study why some families do not participate and what factors affect immune response to the vaccine. The goal is to make prevention more effective and inclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gardasil-9 (HPV vaccine)
What this could lead to: If successful, this could help expand cervical cancer prevention to underserved communities and improve screening accuracy, especially for HIV-positive women.
What could go wrong: This is an observational and interventional study, not a randomized controlled trial. Results may not apply broadly, and participation barriers may limit impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical intraepithelial neoplasia dysplasia of cervix human papilloma virus infection cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL DYSPLASIA

Contacts and locations

Locations

Moi University

Eldoret, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.